A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of VP 20621 for Prevention of Recurrence of Clostridium Difficile Infection (CDI) in Adults Previously Treated for CDI

Approval Date: 4/20/2012

Principal Investigator: Matthew Sims, MD PhD

The objectives of this study are: (1) to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in adults previously treated for CDI; (2) to characterize the frequency and duration of stool colonization with the VP 20621 strain of C. difficile; (3) to evaluate the efficacy of VP 20621 for prevention of recurrence of CDI; and (4)to select a dose regimen of VP 20621 to be used in future studies.


Each study has its own guidelines to determine who can participate, called "eligibility criteria", with only the study doctor able to assess whether you meet all of the eligibility criteria. More information can be found at http://clinicaltrials.gov/ct2/show/NCT01259726.

Contact Person:
Myrene Prystanski-Bette, RN

Status of Clinical Trial: